Browse News

Found 261 articles

• Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

  5/15/2023

  Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the quarter ended March 31, 2023.

• Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

  5/10/2023

  Zevra Therapeutics, Inc. today announced that R. LaDuane Clifton, the Company’s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET.

• Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023

  5/9/2023

  Zevra Therapeutics, Inc. has announced that it will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET, to review its corporate and financial results for the first quarter of 2023.

• Zevra Announces Board of Directors and Leadership Changes

  5/8/2023

  Zevra Therapeutics, Inc. today announced changes to the Company’s Board of Directors (“Board”) and leadership. At the Company’s recent 2023 Annual Meeting of Stockholders (“Annual Meeting”), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevra’s Board.

• Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy

  5/3/2023

  Zevra Therapeutics, Inc. today announced the acceptance of an Investigational New Drug (“IND”) application by the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy which is expected to provide additional information regarding the optimal dosing regimen.

• Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy

  4/17/2023

  Zevra Therapeutics, Inc. announced that leading proxy advisory firms Institutional Shareholder Services and Glass Lewis & Co. have voiced their support for Zevra’s nominees and strategy and found that Mangless’ arguments and nominees were not compelling.

• Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy

  4/4/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy.

• Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors

  3/30/2023

  Zevra Therapeutics announced that it has appointed Wendy L. Dixon, Ph.D., to the Company’s Board of Directors, effective immediately following the conclusion of the 2023 Annual Meeting of Stockholders, to fill the vacancy resulting from Dr. Travis Mickle’s resignation from the Board effective as of the day of the 2023 Annual Meeting to be held on April 25, 2023.

• Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative

  3/17/2023

  Zevra Therapeutics, Inc. today announced that it has joined the Sleep Data Initiative as a founding member.

• Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders

  3/15/2023

  Zevra Therapeutics today announced it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”).

• LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates

  3/15/2023

  LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced today that it has initiated a process to explore a range of strategic and financing alternatives, and provided updates.

• Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

  3/7/2023

  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or “the Company,” formerly “KemPharm, Inc.”), a rare disease therapeutics company, today reported its financial results for the fourth quarter and year ended December 31, 2022. 

• Zevra Therapeutics to Present at 35th Annual Roth Conference

  3/6/2023

  Zevra Therapeutics, Inc. today announced that Richard W. Pascoe, the Company’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT.

• Zevra Therapeutics Begins Trading as ZVRA

  3/1/2023

  Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol “ZVRA” on the Nasdaq Global Select Market at market open today, March 1, 2023.

• 

  AstraZeneca Rare Disease R&D Expansion Adds 500 Jobs At New Hub

  2/28/2023

  On Rare Disease Day, Feburary 28, AstraZeneca announced the creation of the Alexion, AstraZeneca Rare Disease Development Hub in Toronto, Ontario.

• Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

  2/28/2023

  Zevra Therapeutics, Inc. announced that it has become a Corporate Council member of the National Organization for Rare Disorders and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023.

• Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

  2/27/2023

  Zevra Therapeutics, Inc., announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s 2023 Annual Meeting of Stockholders, which is scheduled to take place on April 25, 2023.

• Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

  2/27/2023

  Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022.

• Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

  2/24/2023

  Zevra Therapeutics, Inc. today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed as a treatment for Niemann-Pick disease type C (NPC), is being featured in two poster presentations during the 19th Annual WORLDSymposium™ 2023, the annual research conference dedicated to lysosomal diseases being held February 22-26, 2023 in Orlando, Florida, USA.

• Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

  2/23/2023

  Zevra Therapeutics, Inc. has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), including advancing understanding of NPC disease progression have been accepted for poster presentations at the 19th Annual WORLD Symposium ™ 2023.